Health Canada approved the first generic version of semaglutide (Ozempic), Novo Nordisk's popular diabetes and weight-loss drug. This means Canadian patients may soon have access to a cheaper alternative to the brand-name version.

• •Health Canada approved the first generic version of Ozempic (semaglutide).
• •Approval covers Novo Nordisk's diabetes and weight-loss drug.
• •Canadian patients may gain access to a cheaper alternative to the brand.

Apotex, a Canadian drugmaker, got approval from Health Canada to sell a generic copy of Ozempic (semaglutide), a popular weight-loss and diabetes medicine. This is the first generic version approved by Canada's health regulator.

• •Apotex received Health Canada approval for a generic equivalent of Ozempic (semaglutide)
• •First Canadian-based pharma company to win generic Ozempic approval in Canada

Canada approved a generic version of semaglutide (the active ingredient in Ozempic) made by Dr. Reddy's Laboratories. This generic copy is cheaper and could give more people access to the weight-loss and diabetes drug.

• •Canada approved Dr. Reddy's generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic
• •Generic is cheaper and aims to broaden access for diabetes and weight loss

Dr. Reddy's Laboratories received approval from Health Canada to sell a generic version of semaglutide injection in Canada. This is the first generic copy of the popular weight-loss and diabetes drug to be approved there.

• •Dr. Reddy's received Health Canada approval for generic semaglutide injection
• •First generic semaglutide approved in Canada
• •Approval covers weight-loss and diabetes indications

Canada's health authority approved the first generic copy of semaglutide (Ozempic), the popular weight-loss and diabetes drug. This approval means cheaper versions of the medicine may become available as more companies compete to make GLP-1 drugs.

• •Canada approved the first generic version of semaglutide (Ozempic)
• •Approval opens the door to cheaper GLP-1 alternatives in Canada
• •Decision arrives amid rising competition in the GLP-1 class

Canada approved a generic version of semaglutide, the active ingredient in Ozempic. This means Canadian patients may have access to a cheaper alternative to the brand-name weight-loss and diabetes drug.

• •Canada approved a generic version of semaglutide, the active ingredient in Ozempic.
• •Generic entry positions Canadian patients for a cheaper alternative to brand-name Ozempic.

Canada's health regulator approved a second generic copy of semaglutide (Ozempic), the popular diabetes and weight-loss drug made by Novo Nordisk. More generic options could help lower costs for patients in Canada.

• •Canada's health regulator approved a second generic version of semaglutide (Ozempic)
• •Ozempic is made by Novo Nordisk
• •More generic options could help lower costs for patients in Canada

Canada's health authority approved a second generic version of semaglutide (Ozempic), the popular weight-loss and diabetes drug. More generic copies available could lower prices and help more people afford the medicine.

• •Canada approved a second generic version of semaglutide (Ozempic)
• •Additional generics expected to lower prices and broaden access

Health Canada approved a second generic version of semaglutide (the active ingredient in Ozempic), made by a Canadian company. This gives patients another cheaper alternative to the brand-name weight-loss and diabetes drug.

• •Health Canada approved a second generic version of semaglutide
• •The generic is manufactured by a Canadian company
• •Ozempic is Novo Nordisk's branded semaglutide for diabetes and weight loss

Canada approved a second generic version of Ozempic (a semaglutide injection used for diabetes and weight loss). This expands access to cheaper copies of the drug beyond Novo Nordisk's brand-name version.

• •Canada approved a second generic version of Ozempic (semaglutide injection)
• •Generic is indicated for diabetes and weight loss
• •Approval adds a second copycat competing with Novo Nordisk's brand

Canada has approved a second generic copy of semaglutide (the drug in Ozempic). This means more affordable versions of the popular weight-loss and diabetes medicine are becoming available to Canadian patients.

• •Canada approved a second generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic

Novo Nordisk's oral form of Ozempic (a GLP-1 peptide drug for type 2 diabetes) has FDA approval and will soon be available in the United States. This is the first FDA-approved pill version of a GLP-1 peptide medication for adults with type 2 diabetes.

• •FDA approved Novo Nordisk's oral Ozempic for adults with type 2 diabetes
• •Positioned as the only FDA-approved oral peptide GLP-1 for T2D
• •US launch imminent per Novo Nordisk

Novo Nordisk's oral version of Ozempic (a GLP-1 peptide drug used for type 2 diabetes) will become available in the United States soon. This is the only FDA-approved pill form of this type of medication for adults with diabetes.

• •Novo Nordisk's oral Ozempic to become available in the US soon
• •Only FDA-approved oral peptide GLP-1 for adults with type 2 diabetes

Novo Nordisk is making Ozempic tablets (semaglutide) available across the United States starting May 4. This is a pill version of the weight-loss and diabetes drug that was previously only available as an injection.

• •Novo Nordisk to make Ozempic tablets (semaglutide) available across the US starting May 4
• •Pill version of a drug previously available only as an injection

Dr. Reddy's has received approval to sell a generic version of semaglutide (Ozempic), a popular weight-loss and diabetes drug. The article indicates pricing information for this generic option will be available, potentially offering a lower-cost alternative to the brand-name version.

• •Dr Reddy's received approval to sell a generic version of semaglutide (Ozempic)
• •Generic launch positioned as lower-cost alternative to brand-name Ozempic

Dr. Reddy's Laboratories received approval from Health Canada (the Canadian health regulator) to sell a generic version of semaglutide injection in 2 mg and 4 mg pen formats. This approval means Canadians will have access to a cheaper copy of this popular weight-loss and diabetes drug.

• •Health Canada approved Dr. Reddy's generic semaglutide injection
• •Approval covers 2 mg and 4 mg pen formats